| name | ata-ppgl-genetic-marker-interpretation-for-mets |
| description | This skill interprets SDHx and fumarate hydratase gene variants to assess metastasis risk in pheochromocytoma and paraganglioma patients. Triggered by identification of SDHB pathogenic variant (or negative SDHB immunostaining), FH variant, or other SDHx mutations when a clinician asks how genetic results affect metastasis risk assessment. |
Interpret genetic markers for metastasis risk in pheochromocytoma and paraganglioma
STEP 1 — Gather Information
Collect genetic test results (SDHx, FH, SDHB), SDHB immunostaining status, tumor size, necrosis, vascular invasion, S100 expression, catecholamine phenotype (adrenergic/noradrenergic), age at diagnosis, and tumor location (adrenal vs extra-adrenal).
STEP 2 — Rule In / Rule Out
If a pathogenic SDHB variant is present or SDHB immunostaining is negative, rule in high metastasis risk; otherwise, rule out high risk based solely on SDHB and proceed to COPPS scoring.
STEP 3 — Classify or Stratify
For SDHB-positive cases, classify as high metastasis risk (35‑75%); for SDHB‑negative cases, calculate the COPPS score (tumor size, necrosis, vascular invasion, S100 loss, SDHB immunostaining) and stratify risk as low (0‑1), intermediate (2), or high (≥3).
STEP 4 — Decide
If high risk (SDHB variant or COPPS ≥3), initiate intensified surveillance (imaging every 6‑12 months, genetic counseling, discuss prophylactic interventions); if low/intermediate risk, follow standard postoperative surveillance (annual biochemical testing and imaging).
Clinical Guardrails / Mimics / Pitfalls
Do not rely exclusively on SDHB immunostaining without confirmatory genetic testing; FH variants confer risk but data are limited; avoid missing metastatic PPGL in SDHB‑negative cases by neglecting tumor size, necrosis, or catecholamine phenotype; do not substitute genetic testing for clinical follow‑up in young patients with large tumors.
Concrete Clinical Example
A 45‑year‑old patient with an extra‑adrenal PGL (5 cm) undergoes genetic testing and is found to harbor an SDHB pathogenic variant; SDHB immunostaining is negative. The lesion shows necrosis. Based on the SDHB variant, the patient is classified as high metastasis risk and is scheduled for 6‑monthly 18F‑FDG PET/CT and annual MRI, with referral for genetic counseling.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165
